UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.
Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new d
Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinica
A new clinical trial is hoping to show that treatment with a psychedelic drug in development at UK startup Beckley Psytech could help people battling alcohol use disorder
Psychedelic medicines company Beckley Psytech has reached an agreement to acquire its rival Eleusis Therapeutics, in alignment with predictions that the sector is heading for a period of co
